Cyclic Prolyl Glycine Neurogenesis for Cognitive and Depression Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for cognitive impairment and neurodegenerative disorders, such as Alzheimer's disease, are inadequate in halting or slowing disease progression and often come with undesirable side effects, while existing treatments for depression also pose significant risks, including suicidal tendencies.
Innovation Solution
Cyclic Prolyl Glycine (cPG) and its analogues, which promote neurogenesis and neuronal regeneration, are administered to treat and prevent cognitive impairment, neurodegenerative disorders, and depression by stimulating the formation of new neurons and glial cells, and modulating intracellular signaling pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies for cognitive impairment and neurodegenerative disorders are used, then disease progression can be treated, but undesirable side effects occur and effectiveness in halting or slowing progression is inadequate
Solution Approach 1:
The patent changes the chemical parameter by using cyclic Prolyl Glycine and its analogues instead of conventional therapies. These compounds promote neurogenesis and neuronal regeneration through unique mechanisms that differ from existing treatments, achieving better effectiveness in halting disease progression while minimizing side effects.
Solution Approach 2:
The cyclic Prolyl Glycine compounds act as intermediaries that modulate intracellular signaling pathways to promote neurogenesis. They serve as mediators between external treatment and cellular responses, enabling therapeutic effects through controlled activation of neurogenic pathways without the harsh side effects of conventional therapies.
2Reliability
If existing treatments for depression are used, then depressive symptoms can be addressed, but significant risks including suicidal tendencies occur
Solution Approach 1:
The patent converts the approach by using compounds that promote neurogenesis and neuronal regeneration, transforming the treatment mechanism from one that manages symptoms to one that actively repairs and regenerates neural tissue. This converts a potentially harmful symptom-management approach into a beneficial regeneration-based therapy that reduces suicidal tendencies.
Solution Approach 2:
The treatment changes the fundamental parameter from symptom management to neural regeneration. Cyclic Prolyl Glycine and its analogues alter the therapeutic parameter by promoting the formation of new neurons and glial cells, addressing the root cause rather than merely managing depressive symptoms.
3Productivity
If conventional therapies are used for cognitive impairment, then some symptoms can be managed, but they are inadequate in promoting neuronal regeneration and cognitive recovery
Solution Approach 1:
The patent applies preliminary action by promoting neurogenesis and neuronal regeneration before significant cognitive decline occurs. Cyclic Prolyl Glycine and its analogues prepare and protect neural tissue by stimulating the formation of new neurons and glial cells in advance, preventing rather than just treating cognitive impairment.
Solution Approach 2:
The treatment changes the therapeutic parameter from symptom management to active neuronal regeneration. The cyclic Prolyl Glycine compounds directly stimulate neurogenesis and promote the regeneration of damaged neurons, fundamentally altering the approach from managing cognitive symptoms to actively recovering neural function.
Data Source
AI summary
The present invention generally relates to the use of cyclic Prolyl Glycine (“cyclic PG” or “cPG”) and analogues and mimetics thereof, as neuroprotective agents for the treatment and or prevention of cognitive impairment and neurological disorders including but not limited to cerebral ischemia or cerebral infarction, status epilepticus, perinatal asphyxia, anoxia, and cerebral trauma, as well as to the treatment and prevention of chronic neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and Dementia with Lewy Bodies. The present invention also generally provides manufacturing methods to prepare dosage forms. The present invention further generally relates to the use of cyclic Prolyl Glycine and analogues and mimetics thereof, as neuroprotective and neuro-regenerating agents for the treatment and or prevention of depression and other psychological disorders.